First clinical study of the selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache.
Granisetron (BRL 43694), a selective 5-HT3 receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but 1 patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.
Couturier
E G
EG
Princess Margaret Migraine Clinic, Charing Cross Hospital, London, United Kingdom.
Hering
R
R
Foster
C A
CA
Steiner
T J
TJ
Clifford Rose
F
F
D000328:Adult; D017829:Granisetron; D006801:Humans; D007191:Indazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*
D017829:Granisetron; D007191:Indazoles; D012702:Serotonin Antagonists